Status:
RECRUITING
Histamine as a Molecular Transducer of Adaptation to Exercise
Lead Sponsor:
University of Oregon
Conditions:
Postexercise Hypotension
Eligibility:
All Genders
18-40 years
Phase:
EARLY_PHASE1
Brief Summary
This study is investigating the role of histamine in generating adaptation to exercise
Detailed Description
Exercise promotes and maintains healthy cardiovascular, musculoskeletal, and metabolic function, but the signals and mechanisms which transduce these effects are poorly understood. Histamine plays a r...
Eligibility Criteria
Inclusion
- Age 18 -40
Exclusion
- Systolic ≥ 120
- Diastolic ≥ 80
- Body mass index (BMI) ˃ 28 kg/m2
- Prior diagnosis of cardiovascular disease, diabetes, autonomic disorders, or asthma
- Smoking or nicotine use
- Ongoing medical therapy (other than birth control)
- Ongoing use of over-the-counter or prescription antihistamines
- Allergies or hypersensitivities to drugs, local anesthetics, skin disinfectants, adhesives, or latex
- Pregnant, breastfeeding subjects, or planning to become pregnant in the next 12 months
- Mobility restrictions that interfere with physical activity
- High physical activity based on International Physical Activity Questionaire (IPAQ1)
- Non-English speaking
Key Trial Info
Start Date :
July 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05206227
Start Date
July 28 2021
End Date
December 31 2026
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oregon
Eugene, Oregon, United States, 97403